Translocation Products in Acute Myeloid Leukemia Activate the Wnt Signaling Pathway in Hematopoietic Cells

Molecular and Cellular Biology

Volumn 24, Issue 7, 2004, Pages 2890-2904

  Müller Tidow, Carsten ^a   Steffen, Björn ^a   Cauvet, Thomas ^a   Tickenbrock, Lara ^a   Ji, Ping ^a   Diederichs, Sven ^a   Sargin, Bülent ^a   Köhler, Gabriele ^b   Stelljes, Matthias ^a   Puccetti, Elena ^c   Ruthardt, Martin ^c   DeVos, Sven ^d   Hiebert, Scott W ^e   Koeffler, H Phillip ^d   Berdel, Wolfgang E ^a   Serve, Hubert ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE MYELOID LEUKEMIA ASSOCIATED TRANSLOCATION PRODUCT; BETA CATENIN; CARRIER PROTEIN; CYCLIN D1; GENE PRODUCT; HYBRID PROTEIN; PLAKOGLOBIN; PLZF RETINOIC ACID RECEPTOR ALPHA; PML RETINOIC ACID RECEPTOR ALPHA; PROTEIN AML1 ETO; RETINOIC ACID RECEPTOR ALPHA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENE OVEREXPRESSION; GENE TARGETING; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYTOSKELETAL PROTEINS; DESMOPLAKINS; DNA-BINDING PROTEINS; GAMMA CATENIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOID ENHANCER-BINDING FACTOR 1; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSPLANTATION, ISOGENEIC; WNT PROTEINS; ZEBRAFISH PROTEINS;

MURINAE;

EID: 12144287598     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.24.7.2890-2904.2004     Document Type: Article

References (60)

1. Amann, J. M., J. Nip, D. K. Strom, B. Lutterbach, H. Harada, N. Lenny, J. R. Downing, S. Meyers, and S. W. Hiebert. 2001. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol. 21:6470-6483.
2. Austin, T. W., G. P. Solar, F. C. Ziegler, L. Liem, and W. Matthews. 1997. A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells. Blood 89:3624-3635.
3. Benoit, G., L. Altucci, M. Flexor, S. Ruchaud, J. Lillehaug, W. Raffelsberger, H. Gronemeyer, and M. Lanotte. 1999. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J. 18:7011-7018.
4. Brandon, C., L. M. Eisenberg, and C. A. Eisenberg. 2000. WNT signaling modulates the diversification of hematopoietic cells. Blood 96:4132-4141.
5. Burel, S. A., N. Harakawa, L. Zhou, T. Pabst, D. G. Tenen, and D. E. Zhang. 2001. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol. Cell. Biol. 21:5577-5590.
6. Claverie, J. M. 1999. Computational methods for the identification of differential and coordinated gene expression. Hum. Mol. Genet. 8:1821-1832.
7. Cooper, C. L., and P. E. Newburger. 1998. Differential expression of Id genes in multipotent myeloid progenitor cells: Id-1 is induced by early-and late-acting cytokines while Id-2 is selectively induced by cytokines that drive terminal granulocytic differentiation. J. Cell. Biochem. 71:277-285.
8. Dorsky, R. I., R. T. Moon, and D. W. Raible. 1998. Control of neural crest cell fate by the Wnt signalling pathway. Nature 396:370-373.
9. Easwaran, V., M. Pishvaian, Salimuddin, and S. Byers. 1999. Cross-regulation of beta-catenin-LEF/TCF and retinoid signaling pathways. Curr. Biol. 9:1415-1418.
10. Ferrara, F. F., F. Fazi, A. Bianchini, F. Padula, V. Gelmetti, S. Minucci, M. Mancini, P. G. Pelicci, F. Lo Coco, and C. Nervi. 2001. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61:2-7.
11. Gelmetti, V., J. Zhang, M. Fanelli, S. Minucci, P. G. Pelicci, and M. A. Lazar. 1998. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol. Cell. Biol. 18:7185-7191.
12. Grignani, F., S. De Matteis, C. Nervi, L. Tomassoni, V. Gelmetti, M. Cioce, M. Fanelli, M. Ruthardt, F. F. Ferrara, I. Zamir, C. Seiser, M. A. Lazar, S. Minucci, and P. G. Pelicci. 1998. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391:815-818.
13. Grignani, F., P. F. Ferrucci, U. Testa, G. Talamo, M. Fagioli, M. Alcalay, A. Mencarelli, C. Peschle, I. Nicoletti, and P. G. Pelicci. 1993. The acute promyelocytic leukaemia specific PML/RARa fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74:423-429.
14. Grignani, F., T. Kinsella, A. Mencarelli, M. Valtieri, D. Riganelli, L. Lanfrancone, C. Peschle, G. P. Nolan, and P. G. Pelicci. 1998. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res. 58:14-19.
15. Grisolano, J. L., R. L. Wesselschmidt, P. G. Pelicci, and T. J. Ley. 1997. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89:376-387.
16. He, T. C., A. B. Sparks, C. Rago, H. Hermeking, L. Zawel, L. T. da Costa, P. J. Morin, B. Vogelstein, and K. W. Kinzler. 1998. Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512.
17. Higuchi, M., D. O'Brien, P. Kumaravelu, N. Lenny, E. J. Yeoh, and J. R. Downing. 2002. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1:63-74.
18. Ishiguro, A., K. S. Spirin, M. Shiohara, A. Tobler, A. F. Gombart, M. A. Israel, J. D. Norton, and H. P. Koeffler. 1996. Id2 expression increases with differentiation of human myeloid cells. Blood 87:5225-5231.
19. Johansen, L. M., A. Iwama, T. A. Lodie, K. Sasaki, D. W. Felsher, T. R. Golub, and D. G. Tenen. 2001. c-Myc is a critical target for c/EBPα in granulopoiesis. Mol. Cell. Biol. 21:3789-3806.
20. Kai, H., A. Hisatsune, T. Chihara, A. Uto, A. Kokusho, T. Miyata, and C. Basbaum. 1999. Myeloid ELF-1-like factor up-regulates lysozyme transcription in epithelial cells. J. Biol. Chem. 274:20098-20102.
21. Kirmizis, A., S. M. Bartley, and P. J. Farnham. 2003. Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol. Cancer Ther. 2:113-121.
22. Kolligs, F. T., B. Kolligs, K. M. Hajra, G. Hu, M. Tani, K. R. Cho, and E. R. Fearon. 2000. gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev. 14: 1319-1331.
23. Kozopas, K. M., C. H. Samos, and R. Nusse. 1998. DWnt-2, a Drosophila Wnt gene required for the development of the male reproductive tract, specifies a sexually dimorphic cell fate. Genes Dev. 12:1155-1165.
24. Licht, J. D. 2001. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 20:5660-5679.
25. Linggi, B., C. Müller-Tidow, L. Van De Locht, M. Hu, J. Nip, H. Serve, W. E. Berdel, B. Van Der Reijden, D. E. Quelle, J. D. Rowley, J. Cleveland, J. H. Jansen, P. P. Pandolfi, and S. W. Hiebert. 2002. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat. Med. 8:743-750.
26. Look, A. T. 1997. Oncogenic transcription factors in the human acute leukemias. Science 278:1059-1064.
27. Mao, S., R. C. Frank, J. Zhang, Y. Miyazaki, and S. D. Nimer. 1999. Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias. Mol. Cell. Biol. 19:3635-3644.
28. Mariadason, J. M., G. A. Corner, and L. H. Augenlicht. 2000. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 60:4561-4572.
29. Melnick, A., G. W. Carlile, M. J. McConnell, A. Polinger, S. W. Hiebert, and J. D. Licht. 2000. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood 96:3939-3947.
30. Melnick, A., and J. D. Licht. 1999. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167-3215.
31. Miller, J. R., and R. T. Moon. 1997. Analysis of the signaling activities of localization mutants of beta-catenin during axis specification in Xenopus. J. Cell Biol. 139:229-243.
32. Minucci, S., M. Maccarana, M. Cioce, P. De Luca, V. Gelmetti, S. Segalla, L. Di Croce, S. Giavara, C. Matteucci, A. Gobbi, A. Bianchini, E. Colombo, I. Schiavoni, G. Badaracco, X. Hu, M. A. Lazar, N. Landsberger, C. Nervi, and P. G. Pelicci. 2000. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol. Cell 5:811-820.
33. Miyazaki, Y., X. Sun, H. Uchida, J. Zhang, and S. Nimer. 1996. MEF, a novel transcription factor with an Elf-1 like DNA binding domain but distinct transcriptional activating properties. Oncogene 13:1721-1729.
34. Mizuki, M., R. Fenski, H. Halfter, I. Matsumura, R. Schmidt, C. Muller, W. Gruning, K. Kratz-Albers, S. Serve, C. Steur, T. Buchner, J. Kienast, Y. Kanakura, W. E. Berdel, and H. Serve. 2000. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96:3907-3914.
35. Müller, C., C. Readhead, S. Diederichs, G. Idos, R. Yang, N. Tidow, H. Serve, W. E. Berdel, and H. P. Koeffler. 2000. Methylation of the cyclin A1 promoter correlates with gene silencing in somatic cell lines, while tissue-specific expression of cyclin A1 is methylation independent. Mol. Cell. Biol. 20:3316-3329.
36. Müller, C., R. Yang, D. J. Park, H. Serve, W. E. Berdel, and H. P. Koeffler. 2000. The aberrant fusion proteins PML-RAR alpha and PLZF-RAR alpha contribute to the overexpression of cyclin A1 in acute promyelocytic leukemia. Blood 96:3894-3899.
37. Müller-Tidow, C., R. Metzger, K. Kügler, S. Diederichs, G. Idos, M. Thomas, B. Dockhorn-Dworniczak, P. M. Schneider, H. P. Koeffler, W. E. Berdel, and H. Serve. 2001. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res. 61:647-653.
38. Müller-Tidow, C., W. Wang, G. E. Idos, S. Diederichs, R. Yang, C. Readhead, W. E. Berdel, H. Serve, M. Saville, R. Watson, and H. P. Koeffler. 2001. Cyclin A1 directly interacts with B-myb and cyclin A1/cdk2 phosphorylate B-myb at functionally important serine and threonine residues: tissue-specific regulation of B-myb function. Blood 97:2091-2097.
39. Mulloy, J. C., J. Cammenga, K. L. MacKenzie, F. J. Berguido, M. A. Moore, and S. D. Nimer. 2002. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 99:15-23.
40. Murdoch, B., K. Chadwick, M. Martin, F. Shojaei, K. V. Shah, L. Gallacher, R. T. Moon, and M. Bhatia. 2003. Wnt-5A augments repopulating capacity and primitive hematopoietic development of human blood stem cells in vivo. Proc. Natl. Acad. Sci. USA 100:3422-3427.
41. Pabst, T., B. U. Mueller, N. Harakawa, C. Schoch, T. Haferlach, G. Behre, W. Hiddemann, D. E. Zhang, and D. G. Tenen. 2001. AML1-ETO down-regulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia. Nat. Med. 7:444-451.
42. Pabst, T., B. U. Mueller, P. Zhang, H. S. Radomska, S. Narravula, S. Schnittger, G. Behre, W. Hiddemann, and D. G. Tenen. 2001. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPα), in acute myeloid leukemia. Nat. Genet. 27:263-270.
43. Polakis, P. 2000. Wnt signaling and cancer. Genes Dev. 14:1837-1851.
44. Potter, E., S. Braun, U. Lehmann, and G. Brabant. 2001. Molecular cloning of a functional promoter of the human plakoglobin gene. Eur. J. Endocrinol. 145:625-633.
45. Radomska, H. S., C. S. Huettner, P. Zhang, T. Cheng, D. T. Scadden, and D. G. Tenen. 1998. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol. Cell. Biol. 18:4301-4314.
46. Reya, T., A. W. Duncan, L. Ailles, J. Domen, D. C. Scherer, K. Willert, L. Hintz, R. Nusse, and I. L. Weissman. 2003. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423:409-414.
47. Ross, S. E., N. Hemati, K. A. Longo, C. N. Bennett, P. C. Lucas, R. L. Erickson, and O. A. MacDougald. 2000. Inhibition of adipogenesis by Wnt signaling. Science 289:950-953.
48. Ruthardt, M., U. Testa, C. Nervi, P. F. Ferrucci, F. Grignani, E. Puccetti, C. Peschle, and P. G. Pelicci. 1997. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RARα) and PLZF-RARα fusion proteins on retinoic acid signaling. Mol. Cell. Biol. 17:4859-4869.
49. Sadot, E., I. Simcha, K. Iwai, A. Ciechanover, B. Geiger, and A. Ben-Ze'ev. 2000. Differential interaction of plakoglobin and beta-catenin with the ubiquitin-proteasome system. Oncogene 19:1992-2001.
50. Shtutman, M., J. Zhurinsky, M. Oren, E. Levina, and A. Ben-Ze'ev. 2002. PML is a target gene of beta-catenin and plakoglobin, and coactivates beta-catenin-mediated transcription. Cancer Res. 62:5947-5954.
51. Simcha, I., M. Shtutman, D. Salomon, J. Zhurinsky, E. Sadot, B. Geiger, and A. Ben-Ze'ev. 1998. Differential nuclear translocation and transactivation potential of beta-catenin and plakoglobin. J. Cell Biol. 141:1433-1448.
52. Tenen, D. G. 2001. Abnormalities of the CEBP alpha transcription factor: a major target in acute myeloid leukemia. Leukemia 15:688-689.
53. Tetsu, O., and F. McCormick. 1999. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426.
54. Tonks, A., L. Pearn, A. J. Tonks, L. Pearce, T. Hoy, S. Phillips, J. Fisher, J. R. Downing, A. K. Burnett, and R. L. Darley. 2002. The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 22:22.
55. Tusher, V. G., R. Tibshirani, and G. Chu. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA 98:5116-5121.
56. Weinmann, A. S., S. M. Bartley, T. Zhang, M. Q. Zhang, and P. J. Farnham. 2001. Use of chromatin immunoprecipitation to clone novel E2F target promoters. Mol. Cell. Biol. 21:6820-6832.
57. Westendorf, J. J., C. M. Yamamoto, N. Lenny, J. R. Downing, M. E. Selsted, and S. W. Hiebert. 1998. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol. Cell. Biol. 18:322-333.
58. Yuan, Y., L. Zhou, T. Miyamoto, H. Iwasaki, N. Harakawa, C. J. Hetherington, S. A. Burel, E. Lagasse, I. L. Weissman, K. Akashi, and D. E. Zhang. 2001. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc. Natl. Acad. Sci. USA 98:10398-10403.
59. Zhang, D. E., P. Zhang, N. D. Wang, C. J. Hetherington, G. J. Darlington, and D. G. Tenen. 1997. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc. Natl. Acad. Sci. USA 94:569-574.
60. Zhurinsky, J., M. Shtutman, and A. Ben-Ze'ev. 2000. Plakoglobin and beta-catenin: protein interactions, regulation and biological roles. J. Cell Sci. 113:3127-3139.